Results 61 to 70 of about 3,615 (71)

Effects of a Novel Compound (AL 721) on HTLV-III Infectivity in Vitro

New England Journal of Medicine, 1985
Fulton T Crews
exaly  

Metabolism, pharmacokinetics and excretion of a potent tachykinin NK1 receptor antagonist (CP-122,721) in rat: Characterization of a novel oxidative pathway

Xenobiotica, 2006
exaly  

Open study of AL-721 treatment of HIV-infected subjects with generalized lymphadenopathy syndrome: An eight week open trial and follow-up

Antiviral Research, 1988
exaly  

Health risk assessment and spatial distribution characteristics of heavy metal pollution in rice samples from a surrounding hydrometallurgy plant area in No. 721 uranium mining, East China

Journal of Geochemical Exploration, 2019
exaly  

Metabolism and excretion of CP-122,721, a non-peptide antagonist of the neurokinin NK1 receptor, in dogs: Identification of the novel cleaved product 5-trifluoromethoxy salicylic acid in plasma

Xenobiotica, 2007
exaly  

Peptides bound endogenously by HLA‐Cw*0304 expressed in LCL 721. 221 cells include a peptide derived from HLA‐E

Tissue Antigens, 1996
exaly  

The mechanism of action of DuP 721, a new antibacterial agent: Effects on macromolecular synthesis

Biochemical and Biophysical Research Communications, 1988
exaly  

Determination of the substance P receptor antagonist CP-122, 721 in plasma by narrow-bore high-performance liquid chromatography-ionspray tandem mass spectrometry

Biomedical Applications, 1997
exaly  

The G.721-Based Speech Information Hiding Approach

2015
exaly  

Oxazolidinones, a new class of synthetic antituberculosis agent in vitro and in vivo activities of DuP-721 against Mycobacterium tuberculosis

Diagnostic Microbiology and Infectious Disease, 1991
exaly